Putting even more emphasis on specialty healthcare, particularly oncology is a rather brave move, in my humble opinion. We'll see if the acquisition of Precision Medicine Group for a decent $2.25 billion is going to pay off for the company in the long run.
There are no replies in this thread yet. Be the first to post a reply below: